Expression of growth hormone-releasing hormone in human primary endometrial carcinomas

Ioulia Chatzistamou, Andrew V Schally, Agatha Pafiti, Hippokratis Kiaris, Helen Koutselini

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Hypothalamic GH-releasing hormone (GHRH) regulates GH release from the pituitary, but an ectopic production of GHRH has been detected in various non-hypothalamic tissues, especially cancers. Objective: To investigate whether endometrial tumors produce GHRH. Methods: Twenty-four endometrioid, three serous papillary (SP), three mixed type endometrioid/ serous papillary adenocarcinomas and one malignant mixed Müllerian tumor (MMMT) were assessed for GHRH immunoreactivity by the polyclonal anti-rabbit antibody SV95 and for the expression of GHRH mRNA by in situ hybridization using an oligonucleotide probe. Results: Increased GHRH immunoreactivity was detected in 15 out of 24 (63%) of the endometrioid tumors, including two out of three (66%) of the mixed type endometrioid/serous adenocarcinomas but not in the three SP or the MMMT tumor. Cytoplasmic staining was detected in all positive cases, while in three of them strong nuclear localization of GHRH was also revealed. In situ hybridization indicated the presence of GHRH mRNA in six cases, all characterized as positive for GHRH immunoreactivity. Conclusion: GHRH is expressed in a subset of endometrial tumors, of the endometrioid type in particular. A paracrine/autocrine role for GHRH in the development of the disease should be considered.

Original languageEnglish
Pages (from-to)381-386
Number of pages6
JournalEuropean Journal of Endocrinology
Volume147
Issue number3
StatePublished - Sep 1 2002
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Endometrial Neoplasms
Hormones
Malignant Mixed Tumor
Neoplasms
In Situ Hybridization
Papillary Adenocarcinoma
Pituitary Hormone-Releasing Hormones
Endometrioid Carcinoma
Messenger RNA
Oligonucleotide Probes
Anti-Idiotypic Antibodies
Staining and Labeling
Rabbits

ASJC Scopus subject areas

  • Endocrinology

Cite this

Expression of growth hormone-releasing hormone in human primary endometrial carcinomas. / Chatzistamou, Ioulia; Schally, Andrew V; Pafiti, Agatha; Kiaris, Hippokratis; Koutselini, Helen.

In: European Journal of Endocrinology, Vol. 147, No. 3, 01.09.2002, p. 381-386.

Research output: Contribution to journalArticle

Chatzistamou, I, Schally, AV, Pafiti, A, Kiaris, H & Koutselini, H 2002, 'Expression of growth hormone-releasing hormone in human primary endometrial carcinomas', European Journal of Endocrinology, vol. 147, no. 3, pp. 381-386.
Chatzistamou, Ioulia ; Schally, Andrew V ; Pafiti, Agatha ; Kiaris, Hippokratis ; Koutselini, Helen. / Expression of growth hormone-releasing hormone in human primary endometrial carcinomas. In: European Journal of Endocrinology. 2002 ; Vol. 147, No. 3. pp. 381-386.
@article{dbb024f13dfe45848cf13ac0991af6ed,
title = "Expression of growth hormone-releasing hormone in human primary endometrial carcinomas",
abstract = "Background: Hypothalamic GH-releasing hormone (GHRH) regulates GH release from the pituitary, but an ectopic production of GHRH has been detected in various non-hypothalamic tissues, especially cancers. Objective: To investigate whether endometrial tumors produce GHRH. Methods: Twenty-four endometrioid, three serous papillary (SP), three mixed type endometrioid/ serous papillary adenocarcinomas and one malignant mixed M{\"u}llerian tumor (MMMT) were assessed for GHRH immunoreactivity by the polyclonal anti-rabbit antibody SV95 and for the expression of GHRH mRNA by in situ hybridization using an oligonucleotide probe. Results: Increased GHRH immunoreactivity was detected in 15 out of 24 (63{\%}) of the endometrioid tumors, including two out of three (66{\%}) of the mixed type endometrioid/serous adenocarcinomas but not in the three SP or the MMMT tumor. Cytoplasmic staining was detected in all positive cases, while in three of them strong nuclear localization of GHRH was also revealed. In situ hybridization indicated the presence of GHRH mRNA in six cases, all characterized as positive for GHRH immunoreactivity. Conclusion: GHRH is expressed in a subset of endometrial tumors, of the endometrioid type in particular. A paracrine/autocrine role for GHRH in the development of the disease should be considered.",
author = "Ioulia Chatzistamou and Schally, {Andrew V} and Agatha Pafiti and Hippokratis Kiaris and Helen Koutselini",
year = "2002",
month = "9",
day = "1",
language = "English",
volume = "147",
pages = "381--386",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Expression of growth hormone-releasing hormone in human primary endometrial carcinomas

AU - Chatzistamou, Ioulia

AU - Schally, Andrew V

AU - Pafiti, Agatha

AU - Kiaris, Hippokratis

AU - Koutselini, Helen

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Background: Hypothalamic GH-releasing hormone (GHRH) regulates GH release from the pituitary, but an ectopic production of GHRH has been detected in various non-hypothalamic tissues, especially cancers. Objective: To investigate whether endometrial tumors produce GHRH. Methods: Twenty-four endometrioid, three serous papillary (SP), three mixed type endometrioid/ serous papillary adenocarcinomas and one malignant mixed Müllerian tumor (MMMT) were assessed for GHRH immunoreactivity by the polyclonal anti-rabbit antibody SV95 and for the expression of GHRH mRNA by in situ hybridization using an oligonucleotide probe. Results: Increased GHRH immunoreactivity was detected in 15 out of 24 (63%) of the endometrioid tumors, including two out of three (66%) of the mixed type endometrioid/serous adenocarcinomas but not in the three SP or the MMMT tumor. Cytoplasmic staining was detected in all positive cases, while in three of them strong nuclear localization of GHRH was also revealed. In situ hybridization indicated the presence of GHRH mRNA in six cases, all characterized as positive for GHRH immunoreactivity. Conclusion: GHRH is expressed in a subset of endometrial tumors, of the endometrioid type in particular. A paracrine/autocrine role for GHRH in the development of the disease should be considered.

AB - Background: Hypothalamic GH-releasing hormone (GHRH) regulates GH release from the pituitary, but an ectopic production of GHRH has been detected in various non-hypothalamic tissues, especially cancers. Objective: To investigate whether endometrial tumors produce GHRH. Methods: Twenty-four endometrioid, three serous papillary (SP), three mixed type endometrioid/ serous papillary adenocarcinomas and one malignant mixed Müllerian tumor (MMMT) were assessed for GHRH immunoreactivity by the polyclonal anti-rabbit antibody SV95 and for the expression of GHRH mRNA by in situ hybridization using an oligonucleotide probe. Results: Increased GHRH immunoreactivity was detected in 15 out of 24 (63%) of the endometrioid tumors, including two out of three (66%) of the mixed type endometrioid/serous adenocarcinomas but not in the three SP or the MMMT tumor. Cytoplasmic staining was detected in all positive cases, while in three of them strong nuclear localization of GHRH was also revealed. In situ hybridization indicated the presence of GHRH mRNA in six cases, all characterized as positive for GHRH immunoreactivity. Conclusion: GHRH is expressed in a subset of endometrial tumors, of the endometrioid type in particular. A paracrine/autocrine role for GHRH in the development of the disease should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0036737731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036737731&partnerID=8YFLogxK

M3 - Article

C2 - 12213676

AN - SCOPUS:0036737731

VL - 147

SP - 381

EP - 386

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 3

ER -